The safety and promising efficacy of anti-CD38 mAb-based treatments has prompted the design and application of CAR T-cell therapies targeting CD38, either as a single antigen or in combination with other antigens (Multi-CAR), which are still in progress for r/r AML (NCT03222674, NCT03473457, NCT04351022), MM (NCT03464916, NCT03767751, NCT03778346, NCT03473496) and B-ALL (NCT03754764, NCT03125577, NCT04430530) patients. This evidence concerns the gene CD38 and acute lymphoblastic leukemia.